Gul Wali Khan | Medicinal Chemistry | Research Excellence Award

Published on by Top Pharmaceutical

Mr. Gul Wali Khan | Medicinal Chemistry | Research Excellence Award

Research Assistant | Vorozhtsov Novosibirsk Institute of Organic Chemistry | Pakistan

Mr. Gul Wali Khan is a Research Assistant in organic chemistry at the Novosibirsk Institute of Organic Chemistry, specializing in organometallic synthesis and characterization. He holds advanced degrees in chemistry with a strong focus on organic and coordination chemistry, including research on ferrocene-based bimetallic complexes and ligand design. His professional experience includes extensive laboratory research involving experimental design, spectroscopic characterization, data analysis, and collaborative scientific reporting, alongside prior academic roles in teaching and mentoring chemistry students. His research focuses on the synthesis, structural analysis, and biological evaluation of metal-based complexes, contributing to the advancement of organometallic chemistry with applications in antimicrobial studies and material science. He has authored peer-reviewed publications in reputable journals and is actively engaged in ongoing research projects, demonstrating consistent scholarly output. His contributions reflect a commitment to high-quality research, interdisciplinary collaboration, and growing academic impact, positioning him as a promising candidate for recognition in research excellence.

Citation Metrics (Google Scholar)

11
8
5
2
0

1

1

1

Citations

Documents

h-index

 


Featured Publications

Chao Song | Drug Discovery and Development | Pharmaceutical Excellence AwardΒ 

Published on by Top Pharmaceutical

Mr. Chao Song | Drug Discovery and Development | Pharmaceutical Excellence AwardΒ 

Guangxi Traditional Chinese Medical University | China

Mr. Chao Song is a PhD researcher at Guangxi University of Traditional Chinese Medicine, specializing in pharmacology, molecular biology, and translational medicine. He holds advanced academic training in biomedical sciences with a focus on traditional Chinese medicine and intervertebral disc disorders. His professional experience includes active participation in multiple provincial and municipal research projects, demonstrating strong collaborative and leadership capabilities in scientific investigations. His research primarily explores intervertebral disc degeneration, immune regulation, cellular senescence, and multi-omics integration, with contributions spanning network pharmacology, metabolomics, and metagenomics. He has authored numerous high-impact SCI publications, including first-author and corresponding-author works in leading journals, reflecting significant influence in his field. His technical expertise includes advanced experimental and analytical methods such as molecular assays, cell and animal studies, and scientific data visualization. His scholarly contributions have been recognized through competitive research funding, patent development, and consistent publication in high-impact journals, underscoring his growing reputation and commitment to advancing pharmaceutical and biomedical research.

Citation Metrics (Google Scholar)

643
480
320
160
0

643

50

11

Citations

Documents

h-index

Shanshan Guo | Pharmacology | Research Excellence Award

Published on by Top Pharmaceutical

Dr. Shanshan Guo | Pharmacology | Research Excellence Award

Principal Investigator | China Academy of Chinese Medical Sciences | China

Dr. Shanshan Guo is a Principal Investigator and Director at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, specializing in pharmacology and integrative medicine with a focus on Chinese materia medica and respiratory diseases. She holds advanced degrees in traditional Chinese medicine, integrated Chinese and Western medicine, and pharmacology, reflecting a strong interdisciplinary academic foundation. Her professional career demonstrates progressive leadership, including roles as Principal Investigator and research lead, where she has directed major pharmacological research initiatives and innovative experimental platforms. Her research centers on antiviral therapeutics, mechanisms of pathogen-host interaction, and safety evaluation of traditional Chinese medicine, supported by extensive publications and impactful contributions to translational medicine. She has successfully led funded projects on broad-spectrum antiviral agents and pharmacodynamic mechanisms of herbal formulations, highlighting her scientific rigor and innovation. Dr. Guo’s work has earned recognition through competitive research funding, leadership responsibilities, and contributions to advancing evidence-based integration of traditional and modern medicine, positioning her as a significant contributor to global pharmaceutical and biomedical research.

Citation Metrics (Google Scholar)

745
560
375
190
0

745

116

15

Citations

Documents

h-index


Top 5 Featured Publications

 

Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Published on by Top Pharmaceutical

Dr. Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Texas Tech University Health Science Center | United States

Dr. Hareesh B. Nair, Ph.D., is a distinguished biochemist and translational scientist whose career spans academia, biotechnology innovation, and advanced research leadership. He completed his academic training in life sciences and biochemistry in India, followed by specialized research fellowships in oxidative lipidomics and hormonal carcinogenesis at leading U.S. institutions. These early experiences laid the foundation for his lifelong commitment to understanding disease mechanisms and developing targeted therapeutic solutions.Dr. Nair’s professional journey reflects a rare blend of deep scientific expertise and strategic research leadership. Over the course of his career, he has held progressive roles ranging from instructor and assistant professor to senior scientist, director, and senior director of translational research and external innovation. His contributions at the University of Texas Health Science Center at San Antonio and the Texas Biomedical Research Institute significantly advanced the fields of breast cancer biology, hormonal carcinogenesis, melanoma signaling pathways, endometriosis, uterine fibroids, and targeted drug delivery. His work also includes pioneering estrogen-dependent cancer research, mechanistic studies on aromatase pathways, development of innovative cancer detection strategies, and creation of non-human primate models for reproductive disorders.At Evestra, Inc., Dr. Nair led multidisciplinary teams driving the translational development of oncology and women’s health therapeutics. He spearheaded multiple preclinical programs, established strategic collaborations, guided biomarker discovery, contributed to regulatory submissions, and supported business development through scientific due diligence. His leadership also resulted in the advancement of first-in-class and best-in-class therapeutic candidates, expansion of oncology pipelines, and successful acquisition of non-dilutive federal funding. His contributions include numerous publications, patents, and project management of large-scale contraceptive development initiatives supported by major global health foundations.In his current academic role at Texas Tech University Health Sciences Center El Paso, Dr. Nair is establishing a cutting-edge research laboratory at the chemistry–biology interface. His group focuses on identifying novel drug targets, decoding disease mechanisms, and transforming molecular insights into preclinical therapeutic strategies for cancers and other complex diseases. He remains deeply engaged in collaborative clinical and translational research, particularly in gynecologic oncology, triple-negative breast cancer, ovarian cancer, and endometrial cancer. His expertise also extends to long-acting contraceptive technologies, anti-HIV formulations, and experimental therapeutics for endometriosis and uterine fibroids.Beyond research, Dr. Nair has served extensively as a scientific review officer, facilitating numerous peer-review panels for federal biomedical research programs. His work has been recognized through multiple competitive honors, travel awards, and scientific achievement distinctions. With a strong commitment to innovation, mentorship, and multidisciplinary collaboration, Dr. Hareesh B. Nair continues to shape the future of translational medicine through impactful research, strategic leadership, and unwavering dedication to improving patient health outcomes.

Profile: Orcid

Featured Publications

Aller, E.β€―J., Nair, H.β€―B., Vadlamudi, R.β€―K., & Viswanadhapalli, S. (2025). Significance of midkine signaling in women’s cancers: novel biomarker and therapeutic target. International Journal of Molecular Sciences, 26(10), 4809.

Blankenship, L., Pratap, U.β€―P., Yang, X., Liu, Z., Altwegg, K.β€―A., Santhamma, B., … Lai, Z. (2022). Inhibition of LIFR blocks adiposity‑driven endometrioid endometrial cancer growth. Cancers, 14(21), 5400.

Nair, H.β€―B., Ford, A., Dick, E.β€―J., Jr., Hill, R.β€―H., Jr., & VandeBerg, J.β€―L. (2014). Modeling sunscreen‑mediated melanoma prevention in the laboratory opossum (Monodelphis domestica). Pigment Cell & Melanoma Research, 27(5), 822‑830.

Nickisch, K., Nair, H.β€―B., Kesavaram, N., Das, B., Garfield, R., Shi, S.β€―Q., … Edwards, D.β€―P. (2013). Synthesis and antiprogestational properties of novel 17‑fluorinated steroids. Steroids, 78(9), 895‑902.

Bhaskaran, S., Dileep, K.β€―V., Deepa, S.β€―S., Sadasivan, C., Klausner, M., Krishnegowda, N.β€―K., … Nair, H.β€―B. (2013). Gossypin as a novel selective dual inhibitor of V‑RAF murine sarcoma viral oncogene homolog B1 and cyclin‑dependent kinase 4 for melanoma. Molecular Cancer Therapeutics, 12(4), 567‑576.

Budrys, N.β€―M., Nair, H.β€―B., Liu, Y.β€―G., Kirma, N.β€―B., Binkley, P.β€―A., Kumar, S., … Tekmal, R.β€―R. (2012). Increased expression of macrophage colony‑stimulating factor and its receptor in patients with endometriosis. Fertility and Sterility, 97(5), 1159‑1165.e1.

Wuting Lu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Wuting Lu | Drug Discovery and Development | Best Researcher Award

Dr. Wuting Lu at Jiangxi Academy of Sciences | China

Dr. Wuting Lu is a dedicated researcher specializing in immunotoxicology, neurobiology, and aquatic toxicology. With a strong academic background and diverse research experience, Dr. Lu has contributed significantly to understanding environmental toxicants and their effects on immunity and neurodevelopment using zebrafish models. He has participated in multiple National Natural Science Foundation of China projects, focusing on mechanisms of high-risk autism genes and their impact on the gut-immune-brain axis. His work has resulted in several high-impact journal publications, advancing knowledge in environmental safety, immunology, and neurobiology. Currently, he serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences.

Publication ProfileΒ 

Orcid

EducationΒ 

Dr. Wuting Lu completed his Ph.D. in Biology at Nanchang University, where his research explored immunotoxicity and neurodevelopmental effects of environmental pollutants. He earned his M.S. in Neurobiology, also from Nanchang University, focusing on molecular and cellular mechanisms in the nervous system. His academic journey began with a B.S. in Aquaculture at Dalian Ocean University, providing him with a strong foundation in aquatic biology and toxicology. This multidisciplinary training enabled him to integrate environmental science, immunology, and neuroscience into his research, developing expertise in both experimental techniques and advanced molecular analysis approaches for investigating complex biological interactions.

ExperienceΒ 

Dr. Wuting Lu professional career includes roles in academic research and laboratory management. He currently serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences, where he investigates immunotoxicity and neurotoxicity mechanisms. Before this, he worked as a Laboratory Technician at Jinggangshan University, gaining hands-on experience in molecular biology, immunology, and laboratory safety management. He has actively participated in several National Natural Science Foundation of China projects, contributing to studies on autism gene regulation, microglial activation, and the gut-immune-brain axis. His multidisciplinary experience spans aquatic toxicology, neurobiology, immunology, and transcriptomic analysis, bridging fundamental research with environmental health concerns.

Awards and HonorsΒ 

Dr. Wuting Lu has received recognition for his research contributions through participation in multiple National Natural Science Foundation of China projects, including studies on the high-risk autism gene CHD8 and its effects on microglial activation and the gut-immune-brain axis. His publications in leading journals, such as Fish & Shellfish Immunology and Ecotoxicology and Environmental Safety, highlight his impactful work on immunotoxicity, neurotoxicity, and antioxidant mechanisms in aquatic organisms. While early in his independent research career, his achievements demonstrate excellence in experimental design, molecular analysis, and scientific communication, positioning him as a promising researcher in environmental health and neuroimmunology fields.

Research FocusΒ 

Dr. Wuting Lu research focuses on immunotoxicity, neurotoxicity, and environmental safety, particularly investigating the effects of environmental toxicants on immune and nervous system development using zebrafish as a model organism. He explores molecular mechanisms underlying pollutant-induced oxidative stress, immune dysregulation, and neurodevelopmental impairments. Additionally, he studies the regulatory roles of genes, such as CHD8, in microglial activation and the gut-immune-brain axis, linking environmental exposures to autism spectrum disorders. His work integrates toxicology, transcriptomics, and neuroimmunology to elucidate pathways of toxicity, identify potential biomarkers, and provide insights into environmental risk assessment, contributing to public health and ecological sustainability research.

Publication Top Notes

Immunotoxicity and neurotoxicity induced by natural borneol and synthetic borneol in zebrafish (Danio rerio)

Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to Nitazoxanide

Conclusion

Overall, Dr. Wuting Lu exhibits a strong research trajectory with impactful publications, interdisciplinary expertise, and contributions to nationally funded projects. His work in environmental toxicology, neurobiology, and molecular mechanisms aligns well with the objectives of the Best Researcher Award. With continued focus on independent project leadership and global collaboration, Dr. Lu has the potential not only to be a strong award candidate but also to emerge as a leading researcher in his field.

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs πŸ’Š, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations πŸ“š, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication ProfileΒ 

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) πŸŽ“. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career πŸ”¬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs πŸ’Š. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society πŸ›οΈ. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level πŸ“ˆ. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🀝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research πŸ’ŠπŸ”¬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr.β€―Qunβ€―Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟀 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚑️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages πŸ›‘οΈ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

  • Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer
  • Design and progress of drug-loading polymeric bead for tumor embolization
  • Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?
  • Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells
  • Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

Wenhu Liu | Pharmacology | Excellence in Research

Published on by Top Pharmaceutical

Prof. Wenhu Liu | Pharmacology | Excellence in ResearchΒ 

Prof. Wenhu Liu, at North Sichuan Medical College, China.

Wenhu Liu, born in February 1980, is a dedicated professor and researcher in the field of cancer pharmacology. He currently serves as the Director of the Medicinal Chemistry Teaching and Research Section at the School of Pharmacy, North Sichuan Medical College. A proud member of the Communist Party of China, Liu has made significant strides in understanding cancer pharmacology, particularly focusing on drug resistance mechanisms. His career reflects a balance of academic rigor, international exposure, and innovation-driven research. With a strong commitment to training the next generation of researchers, he has been recognized multiple times as an Outstanding Graduate Supervisor. Wenhu Liu’s contributions to both education and cancer pharmacology highlight his dedication to advancing the field, while also fostering an environment of collaboration and innovation. He remains committed to addressing the challenges of cancer treatment through his in-depth scientific explorations and academic mentorship.

Professional Profile

Scopus

πŸŽ“ Education

Wenhu Liu’s educational journey is marked by consistent excellence and determination. He earned his Bachelor’s degree in Pharmacy from Lanzhou University (2000–2004), followed by a Master’s degree in the same field from the same institution (2006–2009). Seeking to deepen his expertise, he pursued a Ph.D. at the School of Pharmacy, Chongqing University (2014–2017), where he was recognized as an outstanding student. His academic path reflects a steadfast commitment to pharmacology and cancer research. Liu’s focus on advanced studies laid the foundation for his current research in cancer drug resistance. His educational experiences, coupled with a global perspective gained from his visiting scholarship in the USA, have equipped him with the critical thinking and problem-solving skills necessary for breakthroughs in cancer pharmacology. Liu’s dedication to lifelong learning and knowledge-sharing is evident in his mentorship and teaching roles, shaping the next generation of scientists.

πŸ’Ό Experience

Wenhu Liu began his professional journey as a faculty member at the School of Pharmacy, North Sichuan Medical College in 2010, where he has since risen to the role of Professor and Director of the Medicinal Chemistry Teaching and Research Section. His academic career has been marked by continuous learning and global exposure, including a visiting scholarship at the University of Toledo, USA (2013). Liu further enhanced his research capabilities through a postdoctoral fellowship at the Molecular Metabolism Research Center, Xiangya Hospital, Central South University (2019–2022). His extensive experience includes pioneering work on cancer drug resistance and metabolic signaling pathways, resulting in multiple publications and research grants. As a leader, Wenhu Liu fosters an environment of innovation and excellence, guiding students and colleagues alike. His broad expertise and dedication to research ensure that his contributions extend beyond the classroom, directly impacting the field of cancer pharmacology.

πŸ”¬ Research Interests

Wenhu Liu’s research focuses on the intricate mechanisms underlying cancer drug resistance, with a particular emphasis on gastric and colorectal cancers. His work delves into the signaling pathways that drive resistance to drugs like trastuzumab and oxaliplatin, aiming to overcome these hurdles in cancer therapy. Projects such as the investigation of HES1-mediated regulation via the TP53/SLC7A11/GPX4 axis and the RUNX3/E2F1/CHK1 signaling pathway highlight his commitment to unraveling these complex biological processes. Liu also explores the potential of natural compounds, like Panax Notoginseng saponins, in metabolic regulation and cancer treatment. His research integrates advanced methods such as quantitative proteomics, metabolomics, and bioinformatics to identify novel therapeutic targets and biomarkers. Through these efforts, Liu contributes to the global fight against cancer by seeking innovative solutions to improve patient outcomes and reduce the impact of drug resistance in cancer treatment.

πŸ† AwardsΒ 

Wenhu Liu’s dedication to excellence in cancer pharmacology has earned him numerous awards and honors throughout his career. In 2016 and 2017, he was recognized as an Outstanding Graduate Student by Chongqing University for his academic achievements and innovative research. His commitment to mentorship and nurturing young scientists has been celebrated with the Outstanding Graduate Supervisor award by the School of Pharmacy, North Sichuan Medical College in both 2023 and 2024. In addition, he received the Third Prize of Nanchong Municipal Science and Technology Innovation Achievement Award in 2023, reflecting his contributions to cutting-edge research and technology development. That same year, Liu’s collaborative efforts were further acknowledged with the Nanchong Top Ten Innovative Team Achievement Award. These accolades underscore Liu’s passion for discovery, mentorship, and impact, cementing his reputation as a leader and role model in cancer pharmacology research and education.

πŸ“šTop Noted Publications

Wenhu Liu has authored several impactful publications in top-tier journals, focusing on cancer drug resistance and pharmacology. His recent work includes:

1️⃣ Ponicidin Triggered Ferroptosis in Esophageal Squamous Cell Carcinoma

  • Journal: Phytomedicine

  • Year: 2025 (In press)

  • Impact Factor: 6.7

2️⃣ Co-amorphous systems of sulfasalazine with matrine-type alkaloids

  • Journal: European Journal of Pharmaceutics and Biopharmaceutics

  • Year: 2024

  • Volume: 203

  • Article Number: 114475

  • Impact Factor: 4.4

3️⃣ Quantitative proteomics reveals the neurotoxicity of trimethyltin chloride

  • Journal: Neurotoxicology

  • Year: 2023

  • Volume: 99

  • Pages: 162–176

  • Impact Factor: 3.4

4️⃣ Serum proteomics unveil characteristic protein biomarkers

  • Journal: Clinical Proteomics

  • Year: 2022

  • Volume: 19

  • Article Number: 18

  • Impact Factor: 5.0

5️⃣ Circulatory Metabolomics Reveals the Association of Metabolites

  • Journal: Frontiers in Physiology

  • Year: 2022

  • Impact Factor: 4.0

6️⃣ Metabolic pathways underlying GATA6 regulation

  • Journal: International Journal of Medical Sciences

  • Year: 2020

  • Volume: 17

  • Issue: 18

  • Pages: 3146–3164

  • Impact Factor: 3.7

7️⃣ Label-free quantitative proteomics

  • Journal: Chinese Journal of Analytical Chemistry

  • Year: 2020

  • Volume: 48

  • Issue: 2

  • Pages: 187–196

  • Impact Factor: 1.2

Conclusion

Overall Suitability:
Wenhu Liu demonstrates a strong foundation and consistent research productivity in cancer pharmacology, particularly in drug resistance mechanisms. His role as a director and his awards for mentorship indicate strong leadership. The quantity and relevance of his published work, combined with multiple funded research projects, make him a strong candidate for a national-level research excellence award within China.

Awatef Sassi | Drug Discovery and Development | Women Researcher Award

Published on by Top Pharmaceutical

Awatef Sassi | Drug Discovery and Development | Women Researcher Award

Dr. Awatef Sassi, Faculty of medicine of sousse, Tunisia

Dr. Awatef Sassi πŸ§¬πŸ”¬ is a distinguished postdoctoral researcher at the Faculty of Medicine of Sousse, specializing in cardiovascular and metabolic research. She earned her Ph.D. in Biological Sciences (2018) from the Faculty of Science of Bizerte, following a Master’s in Vascular Diseases Biology (2011) and a Medical Biotechnology degree (2008). Dr. Sassi has contributed significantly to scientific advancements, securing a patent on anti-hypertensive properties of Rosmarinus officinalis and publishing in high-impact journals. She is actively involved in mentoring medical theses and conducting innovative research in biophysics and applied toxicology. πŸŒΏπŸ“Š

Publication Profile

Orcid

Education

Dr. Awatef Sassi is a distinguished scholar in biological sciences 🧬, biotechnology πŸ₯, and vascular diseases ❀️. With a Ph.D. in Biological Sciences πŸŽ“, a Master’s in Vascular Disease Biology, and a Medical Biotechnology degree, she has demonstrated an unwavering commitment to scientific research πŸ”¬. Her extensive expertise spans innovative biotechnological applications and advancements in vascular health, contributing significantly to the medical and scientific communities. Dr. Sassi’s dedication to excellence and groundbreaking research continues to shape the future of biotechnology and vascular medicine, making her a respected figure in the field 🌟.

ExperienceΒ 

Dr. Awatef Sassi’s postdoctoral research at the Faculty of Medicine in Sousse πŸ₯ has focused on cardio-pulmonary interactions πŸ’“πŸ’¨ and biophysics βš›οΈ, making significant contributions to biomedical sciences. As a dedicated mentor, she has supervised multiple medical theses πŸ“š, showcasing her leadership in academia. Her patented innovation πŸ… on the antihypertensive activity of Rosmarinus officinalis 🌿 (TN 2023/0143) highlights groundbreaking research with potential clinical impact in hypertension treatment πŸ’Š. Through her pioneering work, Dr. Sassi continues to advance medical science, bridging research and practical healthcare solutions for improved cardiovascular health ❀️.

Professional Development

Dr. Awatef Sassi is a dedicated educator and researcher πŸŽ“πŸ”¬, with extensive experience as a lecturer in analytical chemistry βš—οΈ. Her involvement in postgraduate training πŸ“š has strengthened expertise in HPLC/UPLC πŸ’‰, mass spectrometry πŸ§ͺ, and data analysis (SPSS) πŸ“Š. Through her teaching and mentorship, she equips students and researchers with essential analytical and computational skills, fostering scientific excellence. Dr. Sassi’s commitment to professional development ensures that future scientists gain hands-on experience in advanced laboratory techniques, making a lasting impact in biotechnology, pharmacology, and medical sciences πŸ₯🌿.

Research Focus

Dr. Awatef Sassi’s research primarily focuses on phytomedicine 🌿, clinical nutrition πŸ₯—, cardiovascular health ❀️, and pharmaceutical sciences πŸ’Š. Her work explores the therapeutic potential of medicinal plants like Rosmarinus officinalis and Nitraria retusa for conditions such as hypertension, obesity, and lipid disorders. Additionally, she has contributed to cardiovascular interventions πŸ₯, dermatological formulations, and transfusion medicine 🩸. Her studies include randomized clinical trials, pilot studies, and formulation research, highlighting her interdisciplinary approach to natural product-based therapy and clinical pharmacology. Her work significantly impacts personalized medicine, preventive healthcare, and alternative treatment strategies.

Publication Top Notes

The Effect of Rosmarinus officinalis L Infusion Supplementation on Blood Pressure Among Healthy Volunteers and Grade 1 Hypertensive Patients

Antiobesity and Hypolipidemic Potential of Nitraria retusa Extract in Overweight/Obese Women: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Exploring the Effects of Short-Term Daily Intake of Nitraria retusa Tea on Lipid Profile: A Pre-Post, Uncontrolled Pilot Study in Both Healthy and Overweight/Obese Adults

Distal radial approach versus conventional radial approach: a comparative study of feasibility and safety

Formulation and evaluation of topical halofuginone gel using a novel <I>ex vivo</i> model

RHD genotyping and its implication in transfusion practice

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ayaz Ahmed | Drug Discovery and Development | Best Researcher Award

Dr Ayaz Ahmed, ICCBS – University of Karachi, Pakistan

Dr. Ayaz Ahmed πŸ§¬πŸ”¬ is a Principal Investigator and Assistant Professor at the Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), ICCBS, University of Karachi, Pakistan. With a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China, and an M.Sc. in Microbiology from the University of Karachi, his research focuses on microbial profiling, anti-biofilm agents, and infectious disease models. Dr. Ahmed has supervised numerous postgraduate students and received multiple international awards, including recognition from the American Society for Microbiology and Bill & Melinda Gates Foundation. He also leads funded projects on combating antibiotic-resistant pathogens. 🌟

Publication Profile

google scholar

Qualifications

Dr. Ayaz Ahmed holds a Ph.D. in Biochemistry and Molecular Biology from Dalian Medical University, China (2012), and a Master’s in Microbiology from the University of Karachi, Pakistan (2006, First Division). πŸ§¬πŸŽ“ His doctoral research focused on the “Microbial profiling of dental plaque/Biofilm from dental caries and periodontitis patients” and explored the effects of Lactobacillus species on S. mutans biofilm formation. πŸ¦·πŸ”¬ With a strong academic foundation and research expertise in microbiology and molecular biology, Dr. Ayaz contributes significantly to the understanding of microbial interactions in dental health and disease. 🌟

Job Responsibilities

Dr. Ayaz Ahmed is a Principal Investigator at the Cell Biology Lab, where he oversees the Imaging Facility, maintaining high-end fluorescence and light microscopes. He supports students by assisting them in acquiring high-quality images for their theses and manuscripts. Dr. Ahmed also manages the National Animal Facility for Laboratory Animal Research and Care. He supervises routine animal house operations and collaborates with a veterinary doctor to maintain SPF rats, mice, and hamsters. He is responsible for establishing models for infectious diseases and memory deficits to evaluate the efficacy of natural compounds. Dr. Ahmed also conducts toxicological studies and trains students in ethical animal research practices. πŸ§¬πŸ”¬πŸ

Student Supervised

Dr. Ayaz Ahmed and his team of dedicated researchers have made significant strides in their exploration of innovative therapeutic strategies. Among the Ph.D. candidates, Zulfiqar Ahmed’s research on controlling salmonellosis through probiotics in poultry, Binte Zehra’s study on modulating the metastatic potential of NSCLC, and Jazib Shafiq’s investigation into gut dysbiosis and anxiety have all been awarded. Additionally, Afshan Shams, Yamina Usmani, and Shariqa Khuwaja are examining the potential of natural and synthetic compounds in combating oral cancer and other diseases. Several M. Phil. students are also contributing to research on antimicrobial resistance and cancer therapies. πŸ§ͺπŸ”¬πŸ§«

Honors and Awards

Dr. Ayaz Ahmed has earned numerous accolades throughout his distinguished career. In 2024, he received the Award for Collaborative Scientific Achievement from the Institute of Food Science and Technology, Chinese Academy of Agriculture Science, Beijing. He also became an International Federation for Biosafety Association (IFBA) Certified Biological Waste Management Professional and Bio-risk Management Professional in 2023. Dr. Ahmed was selected as a Mentor for the ASM Future Leaders Mentoring Fellowship Program in 2023 and was awarded the Health Security Partner Grant by the Bill & Melinda Gates Foundation in 2021. He has also earned prestigious travel awards and fellowships, including the American Society for Microbiology ID Fellowship and the Science and Technology Talent Award. πŸ…πŸŒπŸ¦ 

Completed Projects

Dr. Ayaz Ahmed has led multiple impactful research projects focused on combating multidrug-resistant microorganisms and improving public health. His research on the effect of synthetic and natural compounds on biofilm formation was funded by the Higher Education Commission of Pakistan (HEC) under project # HEC No: PD-IPFP/HRD/HEC/ 2013/1182. He also contributed to projects such as Personal Protective Equipment for Sindh Poultry Vaccine Center (funded by CRDF Global, USA), and oral pathogens related to dental caries (funded by ICCBS). Notably, his work on antimicrobial-resistant water contaminants, funded by the U.S.-Pakistan Centers for Advanced Studies in Water, aims to improve water quality. He further advanced research on antimicrobial and antibiofilm agents targeting Acinetobacter baumannii and Klebsiella pneumonia with funding from HEC. πŸ’§πŸ”¬πŸ¦ 

Professional Experience

Dr. Ayaz Ahmed has had a distinguished career in academia and research. Since June 2017, he has been serving as an Assistant Professor at the International Center for Chemical and Biological Sciences, University of Karachi. Prior to this, he worked as a Senior Research Officer at the same institution from November 2013 to June 2017. Dr. Ahmed also pursued Post-Doctoral training in Behavioral Sciences at Hunan Drug Safety Evaluation in Changsha, China, from January 2016 to February 2017. His earlier roles include Assistant Professor on Interim Placement, Research Officer in Avian Influenza Vaccine Production, and a research intern in the National Internship Program. πŸ§ͺπŸ“š

Professional Membership

Dr. Ayaz Ahmed is an active member of several prestigious professional organizations, contributing significantly to the fields of microbiology and infectious diseases. His memberships include the American Society for Microbiology (ASM) 🦠, the Pakistan Biological Safety Association (PBSA) 🧫, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 🌍. Additionally, he is a member of the American Association of Cancer Research (AACR) πŸŽ—οΈ and the Medical Microbiology & Infectious Disease Society of Pakistan (MMIDSP) πŸ‡΅πŸ‡°. These memberships reflect his commitment to advancing research and innovation in microbiology, infectious diseases, and cancer research.

Research Focus

Dr. Ayaz Ayaz Ahmed research focus primarily revolves around microbiology, particularly in the fields of gut microbiota analysis, antimicrobial resistance, and biofilm formation. His studies often investigate the interactions between microorganisms and the human or animal host, such as comparing gut microbe profiles between healthy individuals and those with conditions like hyperthyroidism and liver cirrhosis. Additionally, Dr. Ahmed explores innovative therapeutic approaches, including the development of antimicrobial agents, such as nanoparticles conjugated with antibiotics to combat biofilm-forming pathogens like Klebsiella pneumoniae and Staphylococcus aureus. His work has significant implications for medical microbiology and the treatment of infectious diseases. πŸ¦ πŸ”¬

Publication Top Notes

Gut microbe analysis between hyperthyroid and healthy individuals

Phylogenetic and biological characterization of Newcastle disease virus isolates from Pakistan

Biofilm inhibitory effect of chlorhexidine conjugated gold nanoparticles against Klebsiella pneumoniae

Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals

Rifampicin conjugated silver nanoparticles: a new arena for development of antibiofilm potential against methicillin resistant Staphylococcus aureus and Klebsiella pneumoniae

Effect of Lactobacillus species on Streptococcus mutans biofilm formation.

Comparison of oral microbiota in orthodontic patients and healthy individuals

Synthesis and Chemosensing of Nitrofurazone using Olive oil based Silver Nanoparticles (O-AgNPs)

Isolation of dihydrobenzofuran derivatives from ethnomedicinal speciesΒ Polygonum barbatumΒ as anticancer compounds

Victor Ajayi | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Victor Ajayi | Drug Discovery and Development | Best Researcher Award

Mr Victor Ajayi, University of Medical sciences Ondo Nigeria, Nigeria

Mr. Oluwadamilola Victor Ajayi is a distinguished academic and researcher in human physiology 🧬, with a B.Tech, M.Sc., and M.Phil. from reputable institutions. His groundbreaking research focuses on anti-ulcerogenic and antioxidant effects, phytochemical profiling, and bioactive compounds’ therapeutic roles 🩺. With over a decade of teaching experience at UNIMED πŸŽ“, he excels in curriculum development and research mentorship. A member of esteemed bodies like PSN and Physoc πŸ…, Mr. Ajayi actively engages in advancing physiology through publications and conferences. His dedication to science and education makes him a standout contributor in his field 🌍.

Publication Profile

orcid

Educational Backgrounds

Victor Ajayi’s academic journey spans several prestigious institutions. He is currently pursuing an M.Phil in Human Physiology at the Federal University of Technology, Akure (FUTA), starting in November 2024. He previously attended the University of Medical Sciences (UNIMED), Ondo, from August 2022 to December 2024, and earned his M.Sc. in Human Physiology from the University of Ibadan in November 2018. Victor completed his B.Tech in Human Physiology at Ladoke Akintola University of Technology (LAUTECH) in November 2011. His earlier academic milestones include WAEC (2009) and NECO (2002). πŸŽ“πŸ“šπŸ‘¨β€πŸŽ“

Work Experience

Victor Ajayi has a diverse work experience spanning various roles in academia and healthcare. He started with industrial training as a Technologist at Spring Specialist Hospital in 2010, followed by NYSC at Ondo State School of Nursing, where he taught Physiology and Anatomy. Victor later worked as a teacher and guest tutor at different institutions, including Integrity Nursery, Ondo State School of Nursing, and several colleges. At the University of Medical Sciences, he serves as an Assistant Lecturer, course coordinator, and level adviser, while also supervising graduate students. His contributions to Physiology education remain invaluable. πŸ₯πŸ“šπŸ‘¨β€πŸ«

Membership

Mr. Victor Ajayi D. is an active member of esteemed professional bodies such as the Physiological Society of Nigeria (PSN) and The Physiological Society (Physoc). Over the years, he has attended several notable conferences and workshops, including the 28th and 29th Scientific Conferences of PSN at the University of Ilorin in 2008 and 2009, and the 31st conference at Lagos State University in 2011. He also participated in workshops on pedagogy, effective communication, animal ethics, and integrated registration. His dedication to continued learning is evident in his certified seminar attendance, such as the Bioinformatics and Genomics course in October 2024. πŸ“šπŸ”¬πŸ§‘β€πŸ«

Community and Professional Engagement

Mr. Victor Ajayi has consistently showcased remarkable leadership in professional communities. As a dedicated member of esteemed organizations such as the Physiological Society of Nigeria (PSN) and The Physiological Society (Physoc), he has made significant contributions to the advancement of his field. His active participation in numerous conferences and workshops underscores his commitment to continuous learning and staying at the forefront of his profession. Through these engagements, Mr. Ajayi has demonstrated a passion for professional growth and a commitment to fostering collaboration within the scientific community. His involvement continues to inspire and influence others in the field. πŸ’ΌπŸ“š

Accolades and Recognition

Mr. Victor Ajayi has made significant contributions to research, education, and professional development, positioning him as a strong contender for the Best Researcher Award. Although his CV does not highlight specific prior awards, his innovative approaches to addressing physiological challenges and his commitment to advancing scientific knowledge demonstrate his potential. Additionally, his dedication to mentoring the next generation of researchers reflects his passion for nurturing talent and fostering academic growth. Mr. Ajayi’s work continues to inspire and impact the research community, showcasing his outstanding ability to drive change and innovation in his field. πŸ†πŸ“šπŸ”¬

Research Focus

Mr. Victor Ajayi’s research focuses on the anti-inflammatory and anti-oxidative effects of pasteurized yoghurt in mitigating gastric ulceration induced by indomethacin in male Wistar rats. This study delves into gastrointestinal health and the potential therapeutic benefits of food-based interventions in inflammatory conditions. His work contributes to pharmacology, nutritional science, and biomedical research with an emphasis on how diet and natural substances can influence disease progression and provide alternative treatments. This aligns with the field of Pharmacological Toxicology and Gastroenterology, exploring the intersection of nutrition and pharmacology in disease management. πŸ§‘β€βš•οΈπŸ½οΈπŸ’Š

Publication Top Notes

Anti-inflammatory and anti-oxidative effect of pasterurised yoghurt in indomethacin induced gastric ulceration in male Wistar rats